Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Gc Cell Corporation has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners across 2 distinct art units, which indicates that multiple examiners are working within at least one shared administrative group. Having 3 distinct examiners provides the company with a variety of viewpoints on its Biotechnology & Pharmaceuticals applications. This concentration within 2 distinct art units may lead to more consistent procedural requirements despite the variety of examiners. The 3 pending office actions represent the current legal front for the company's innovations.
JACOB A BOECKELMAN is the busiest examiner for the portfolio, currently managing 1 busiest examiner pending action. This examiner is part of the group of 3 distinct examiners handling the company's active cases. The use of 2 distinct art units for 3 pending actions suggests a concentration of technical review within specific biotechnology sectors. This structure may allow for some administrative efficiency while still involving 3 distinct examiners. Practitioners should coordinate across the 2 distinct art units to ensure a unified prosecution strategy for the 1 busiest examiner pending action and other active cases.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOECKELMAN, JACOB A | 1 | 35.2% | +45.6% |
| PAULUS, ERIN VIRGINIA | 1 | 21.1% | +93.8% |
| NGUYEN, QUANG | 1 | 38.0% | +52.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268167 | EXPANDED AND STIMULATED NATURAL KILLER CELLS | PAULUS, ERIN VIRGINIA | 88d overdue |
| 18285648 | TREATMENT OF CANCER WITH NK CELLS AND AN EGFR TARGETED ANTIBODY | BOECKELMAN, JACOB A | — |
| 18004241 | NOVEL TRANSPLANTATION CELLS HAVING REDUCED IMMUNOGENICITY | NGUYEN, QUANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268167 | EXPANDED AND STIMULATED NATURAL KILLER CELLS | PAULUS, ERIN VIRGINIA | 88d overdue |
| 18285648 | TREATMENT OF CANCER WITH NK CELLS AND AN EGFR TARGETED ANTIBODY | BOECKELMAN, JACOB A | — |
| 18004241 | NOVEL TRANSPLANTATION CELLS HAVING REDUCED IMMUNOGENICITY | NGUYEN, QUANG | — |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18285648 | TREATMENT OF CANCER WITH NK CELLS AND AN EGFR TARGETED ANTIBODY | BOECKELMAN, JACOB A | 1655 | §102§103§112 | Non-Final OA | — | Pending | Oct 04, 2023 |
| 18268167 | EXPANDED AND STIMULATED NATURAL KILLER CELLS | PAULUS, ERIN VIRGINIA | 1631 | §101§102§103§112 | Final Rejection | 88d overdue | Pending | Jun 16, 2023 |
| 18004241 | NOVEL TRANSPLANTATION CELLS HAVING REDUCED IMMUNOGENICITY | NGUYEN, QUANG | 1631 | §102§103§112 | Final Rejection | — | Pending | Jan 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial